X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE GLENMARK PHARMA TTK HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 19.2 19.1 100.5% View Chart
P/BV x 4.9 3.4 145.4% View Chart
Dividend Yield % 0.6 0.3 190.2%  

Financials

 TTK HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
GLENMARK PHARMA
Mar-18
TTK HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs663930 71.3%   
Low Rs399517 77.1%   
Sales per share (Unadj.) Rs535.6322.6 166.0%  
Earnings per share (Unadj.) Rs15.928.5 56.0%  
Cash flow per share (Unadj.) Rs20.039.2 51.1%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.80.3 272.5%  
Book value per share (Unadj.) Rs137.6183.0 75.2%  
Shares outstanding (eoy) m7.77282.17 2.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.2 44.2%   
Avg P/E ratio x33.325.4 131.1%  
P/CF ratio (eoy) x26.518.5 143.6%  
Price / Book Value ratio x3.94.0 97.6%  
Dividend payout %25.17.0 357.3%   
Avg Mkt Cap Rs m4,127204,206 2.0%   
No. of employees `0001.713.7 12.5%   
Total wages/salary Rs m60718,718 3.2%   
Avg. sales/employee Rs Th2,436.76,636.8 36.7%   
Avg. wages/employee Rs Th355.21,364.7 26.0%   
Avg. net profit/employee Rs Th72.5586.1 12.4%   
INCOME DATA
Net Sales Rs m4,16291,031 4.6%  
Other income Rs m61914 6.7%   
Total revenues Rs m4,22391,945 4.6%   
Gross profit Rs m19716,154 1.2%  
Depreciation Rs m323,019 1.1%   
Interest Rs m302,856 1.0%   
Profit before tax Rs m19711,193 1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m733,155 2.3%   
Profit after tax Rs m1248,039 1.5%  
Gross profit margin %4.717.7 26.7%  
Effective tax rate %37.028.2 131.3%   
Net profit margin %3.08.8 33.7%  
BALANCE SHEET DATA
Current assets Rs m1,62969,887 2.3%   
Current liabilities Rs m1,05832,879 3.2%   
Net working cap to sales %13.740.7 33.7%  
Current ratio x1.52.1 72.4%  
Inventory Days Days3081 36.6%  
Debtors Days Days3493 35.9%  
Net fixed assets Rs m55628,892 1.9%   
Share capital Rs m78282 27.5%   
"Free" reserves Rs m87851,353 1.7%   
Net worth Rs m1,06951,635 2.1%   
Long term debt Rs m15941,418 0.4%   
Total assets Rs m2,399125,954 1.9%  
Interest coverage x7.64.9 154.0%   
Debt to equity ratio x0.10.8 18.5%  
Sales to assets ratio x1.70.7 240.0%   
Return on assets %6.48.6 74.1%  
Return on equity %11.615.6 74.4%  
Return on capital %18.515.1 122.2%  
Exports to sales %0.80-   
Imports to sales %1.40-   
Exports (fob) Rs m33NA-   
Imports (cif) Rs m58NA-   
Fx inflow Rs m3336,317 0.1%   
Fx outflow Rs m639,720 0.7%   
Net fx Rs m-3026,598 -0.1%   
CASH FLOW
From Operations Rs m12716,481 0.8%  
From Investments Rs m-146-10,133 1.4%  
From Financial Activity Rs m22-4,685 -0.5%  
Net Cashflow Rs m31,770 0.1%  

Share Holding

Indian Promoters % 65.4 48.3 135.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 6.9 53.6%  
FIIs % 5.2 34.4 15.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 10.5 245.7%  
Shareholders   12,723 56,727 22.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FULFORD INDIA  JUBILANT LIFE SCIENCES  BIOCON   

Compare TTK HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 268 Points Higher(Closing)

After opening the day marginally higher, Indian share markets continued their momentum and ended their day on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Mar 19, 2019 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 8-QTR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS